CFO Resigns at Skye Bioscience as CEO Takes Over Financial Duties
SKYE sits 24% above its 52-week low of $1.64.
Summary
CFO John Sharp resigned effective September 8, 2026, and CEO Punit Dhillon has assumed the principal financial and accounting officer role. This follows a turbulent period for Skye: a reverse merger with Redx Pharma that left shareholders with only 5.38% of the combined company, a Nasdaq delisting notice, and insider selling by 5AM Ventures. The CFO departure adds to governance concerns, though the company has secured a $22 million equity line with Redmile Group. The market will watch whether Dhillon can stabilize finances ahead of the merger completion.
At the time of this announcement, SKYE was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9M. The 52-week trading range was $1.64 to $39.92. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.